Open Access

Efficacy of tart cherry juice in reducing muscle pain during running: a randomized controlled trial

  • Kerry S Kuehl1Email author,
  • Erica T Perrier1,
  • Diane L Elliot1 and
  • James C Chesnutt2
Contributed equally
Journal of the International Society of Sports Nutrition20107:17

DOI: 10.1186/1550-2783-7-17

Received: 5 April 2010

Accepted: 7 May 2010

Published: 7 May 2010

Abstract

Background

Long distance running causes acute muscle damage resulting in inflammation and decreased force production. Endurance athletes use NSAIDs during competition to prevent or reduce pain, which carries the risk of adverse effects. Tart cherries, rich in antioxidant and anti-inflammatory properties, may have a protective effect to reduce muscle damage and pain during strenuous exercise. This study aimed to assess the effects of tart cherry juice as compared to a placebo cherry drink on pain among runners in a long distance relay race.

Methods

The design was a randomized, double blind, placebo controlled trial. Fifty-four healthy runners (36 male, 18 female; 35.8 ± 9.6 yrs) ran an average of 26.3 ± 2.5 km over a 24 hour period. Participants ingested 355 mL bottles of tart cherry juice or placebo cherry drink twice daily for 7 days prior to the event and on the day of the race. Participants assessed level of pain on a standard 100 mm Visual Analog Scale (VAS) at baseline, before the race, and after the race.

Results

While both groups reported increased pain after the race, the cherry juice group reported a significantly smaller increase in pain (12 ± 18 mm) compared to the placebo group (37 ± 20 mm) (p < .001). Participants in the cherry juice group were more willing to use the drink in the future (p < 0.001) and reported higher satisfaction with the pain reduction they attributed to the drink (p < 0.001).

Conclusions

Ingesting tart cherry juice for 7 days prior to and during a strenuous running event can minimize post-run muscle pain.

Introduction

Long distance running is known to cause acute muscle damage resulting in acute inflammation [1] and decreased force production [2] that can last up to 1 week post-exercise [3]. One proposed mechanism for this acute response to distance running is that extensive myofibril disruption triggers a local inflammatory response, exacerbating muscle damage [49]. Leukotrienes then increase vascular permeability, attracting neutrophils to the injury site, resulting in free radical production [10]. Among endurance athletes, NSAIDs are used during competition to prevent or reduce pain during a race [11]. There are, however, known adverse effects associated with the use of traditional oral NSAIDs [12], including gastrointestinal, renal, and cardiovascular adverse events. Tart cherries are considered a good source of phenolic compounds with high levels of antioxidant and anti-inflammatory activity [13, 14]. Considering the natural anti-inflammatory and antioxidant capacity of tart cherries, it is plausible that cherry consumption before and during strenuous exercise may have a protective effect to reduce muscle damage and pain.

Consumption of approximately 45 cherries per day has been shown to reduce circulating concentrations of inflammatory markers in healthy men and women [15, 16]. Moreover, a recent study of healthy, exercise-naïve individuals demonstrated efficacy for cherry juice in decreasing symptoms and strength loss following eccentric exercise induced muscle damage. Most notably, there was a preservation of muscle function attributable to the cherry juice [15]. The specific anti-inflammatory mechanism by which cherry juice supplementation may lessen exercise-induced muscle damage is not well understood [16]. However, it is possible that the anti-inflammatory and/or the antioxidant effects of cherry juice may mediate this secondary response and avoid the proliferation of myofibrillar disruption [17]. While there are no studies directly measuring neutrophil and monocyte activation after exercise, this mechanism may represent a potential explanation for the reduction in inflammation and strength losses associated with tart cherry consumption.

The Oregon Hood to Coast relay race presented a unique opportunity to examine the effects of tart cherry juice supplementation on acute muscle damage caused by repeated bouts of running. Covering 315 km from Mt. Hood to the Oregon coast, the race involves relay teams of 12 runners who complete 3 race segments each (individual total running distance: 22.5 to 31.4 km). Crossing two mountain ranges, the hilly course provides ample opportunity for eccentric muscle damage, with individual running segments descending up to 609 m or ascending up to 200 m. The purpose of this study was to assess the effects of tart cherry juice, compared to a placebo cherry drink, on muscle pain among Hood to Coast runners.

Methods

Subjects

Fifty-four healthy runners participating in the Hood to Coast relay (36 male, 18 female; 35.8 ± 9.6 yrs) volunteered to participate. The study was approved by the university's Institutional Review Board and by the Hood to Coast race director, and all participants gave written, informed consent. Inclusion criteria included an ability and willingness to abstain from anti-inflammatory or pain-relieving drugs, and willingness to refrain from seeking any other treatment for symptoms of muscle damage until the completion of the study. Exclusion criteria included recent use of other pain management methods (including acupuncture, transcutaneous electrical nerve stimulation, topical medications/anesthetics, muscle relaxants, injections, or systemic steroids). Women capable of becoming pregnant completed a pregnancy test to rule out pregnancy prior to participation.

Beverage Preparation

Cherry Juice

The cherry juice was prepared by mixing freshly prepared tart cherry juice with commercially available apple juice in a proprietary ratio (Cherrish Inc., Seattle, WA, USA). Frozen tart cultivar Montmorency cherries were used to prepare the cherry juice following standard procedures that simulate industrial processing. The blended juice was pasteurized by heating it to 85°C, hot packed into 10.5 oz plastic bottles with a three minute hold time to achieve commercial sterility, and then forced cooled in a water bath. One 10.5 oz bottle of the juice provided at least 600 mg phenolic compounds, expressed as gallic acid equivalents by the method of Singleton and Rossi [18], and at least 40 mg anthocyanins, calculated as cyanidin-3-glucoside equivalents by the pH differential method described by Giusti and Wrolstad [19]. Each bottle contained the equivalent of 45-50 cherries.

Placebo

The placebo was prepared by mixing unsweetened fruit punch soft drink mix (Kraft Corporation, Ryebrook, New York, USA; ingredients listed: citric acid, salt, calcium phosphate, red 40, artificial flavor, ascorbic acid, blue 1) with water in the proportion recommended by the manufacturer (about 2 g/l). Sugar was added to match the concentration of soluble solids in the cherry juice blend to a final concentration of 13 Brix (total percentage soluble solids by weight). The flavored beverage was then pasteurized and bottled following the procedure used for the juice.

Experimental Design

The design was a randomized, placebo-controlled, double-blind trial among 54 runners participating in the Hood to Coast relay race (Figure 1). Each participant completed 3 running segments during the race, with individual segment distances ranging from 5.6 to 12.4 km and an average total running distance of 26.3 ± 2.5 km. Participants running on the same relay team were assigned to the same drink condition (n = 28 cherry; n = 26 placebo) in order to avoid participants inadvertently switching drinks during the study. Participants completed 3 data collection sessions: Day 1 - Baseline (7 days prior to race), Day 7 - Race Start, and Day 8 - Race End. At Baseline, participants were given 16-355 mL bottles of the drink (cherry juice or placebo) with instructions to consume two bottles daily prior to the race (14 bottles over 7 days), and two bottles during the race (total consumption: 16 bottles). Baseline data collection also included a health screening by a physician blinded to the participant's drink condition. Participants assessed their pain intensity during each visit on a standard 100 mm Visual Analog Scale (VAS), with 0 mm indicating 'no pain', and 100 mm indicating 'most severe pain'. The VAS has excellent reliability for acute pain [20] as well as well-defined thresholds for meaningful change in pain intensity [21]. After finishing the race (Day 8), participants completed the VAS pain scale and a short questionnaire reporting their level of satisfaction with the pain relief they attributed to the drink.
https://static-content.springer.com/image/art%3A10.1186%2F1550-2783-7-17/MediaObjects/12970_2010_Article_167_Fig1_HTML.jpg
Figure 1

Consort diagram of enrolled participants.

Statistical Analysis

Outcome variables were: participants' assessment of pain (VAS), level of satisfaction with the drink, and willingness to use the drink in the future. VAS pain scores were analyzed using [3 (time) × 2 (drink)] mixed-effects regression (SPSS version 16 for Windows, Chicago, IL). Participant satisfaction and participant willingness to use the drink again were analyzed using independent samples t-tests. Level of significance was set at α = 0.05.

Results

Baseline Participant Demographics

Of the 54 participants enrolled, 28 were assigned cherry juice and 26 were assigned the placebo drink (Table 1). A total of 3 participants (2 cherry, 1 placebo) withdrew prior to competing the study (1 was lost to follow-up; 1 reported that the drink caused GI distress; 1 took NSAIDs during study period). Despite the fact that participants were randomized into treatment groups, the cherry group reported significantly higher pain scores than the placebo group on Day 1 (F(1,49) = 8.00; p < 0.01).
Table 1

Participant baseline demographics

 

Placebo

Cherry

N

25

26

Age

32.2 ± 9.8

38.2 ± 8.5

Male/Female

15/10

19/7

Baseline VAS (mm)*

6.1 ± 7.9

16.1 ± 15.9

* Baseline VAS significantly different between groups (p < 0.01)

Pain (VAS) at Race Start and Race End

Mixed-effects regression revealed significant main effects of drink (F(1,49) = 11.50; p < 0.01), time (F(1,49) = 85.51, p < 0.001) as well as an interaction between drink and time (F(1,49) = 22.64, p < 0.001). At Race Start, there were no differences in mean VAS score between the cherry and placebo groups (p = 0.38). After completing the race, participants in both groups reported more pain; however, the increase in pain was significantly smaller in the cherry juice group compared with the placebo group (p < 0.001) (Table 2).
Table 2

Mean pain scores (VAS) at 3 time points (baseline, race start, race end)

 

Day 1 (Baseline)

Day 7 (Race Start)

Day 8 (Race End)

Placebo

6.1 ± 7.9

8.0 ± 9.6

45.3 ± 20.5

Cherry

16.1 ± 15.9*

10.6 ± 11.8

22.6 ± 12.6**

Between groups: * p < 0.05; ** p < 0.001

Participant Satisfaction

Participants in the cherry juice group reported higher willingness to use the drink again (p < 0.001), higher overall satisfaction with the drink (p < 0.001), and higher satisfaction in the pain reduction they attributed to the drink (p < 0.001) (Table 3).
Table 3

Participant satisfaction with drink

Measure

 

Mean Score

p

Willingness to use drink in future (1 = very unwilling; 10 = very willing)

Placebo

5.0 ± 2.5

< 0.001

 

Cherry

8.3 ± 1.3

 

Drink Satisfaction - Pain Relief (1 = very satisfied; 5 = very dissatisfied)

Placebo

3.6 ± 0.9

< 0.001

 

Cherry

2.2 ± 0.6

 

Drink Satisfaction - Overall (1 = very satisfied; 5 = very dissatisfied)

Placebo

3.3 ± 0.8

< 0.001

 

Cherry

2.1 ± 0.5

 

Discussion

It is well-documented that running for distances in excess of typical training distances causes acute muscle injury, and that eccentric muscle actions, such as downhill running, exacerbate injury and soreness [22]. The Hood to Coast relay requires participants to run three separate race segments over an approximately 24 hour period, including segments that ascend or descend steep terrain. It is expected, therefore, that Hood to Coast runners will experience inflammation and pain during the strenuous race. In our study, runners in both groups reported more pain upon completion of the race. However, participants who drank the tart cherry juice twice daily for one week prior to and the day of the race reported a significantly smaller increase in pain after the race (mean post-race increase of 12 mm in the cherry juice group, compared with a 37 mm increase in the placebo group). The relative post-race reduction in pain in the cherry group (25 mm lower VAS than placebo) suggests that tart cherry juice provided a protective benefit against the acute muscle pain caused by distance running.

Pain associated with acute muscle injury is most likely due to oxidative tissue damage which leads to an inflammatory response, causing further production of free radicals and augmenting secondary muscle soreness [2325]. Because of that pathogenesis, nutritional antioxidants have been proposed as a means of mitigating muscle soreness and strength loss caused by damaging exercise [15]. Tart cherries contain flavinoids and anthocyanins, with high antioxidant and anti-inflammatory properties [13, 14]. Consumption of about 45 cherries a day has been shown to reduce circulating inflammatory markers in healthy men and women [16]. Moreover, Kelley et al. reported that serum inflammatory markers including C-reactive protein (CRP) decreased by 25% after 28 days of consuming Bing sweet cherries [26]. Additionally, when studied in healthy young adults, consumption of cherry juice equivalent to 100-120 cherries daily reduced strength loss and pain associated with exercise-induced delayed-onset muscle soreness (DOMS) [15]. In our study, participants consumed two 355 mL bottles of tart cherry juice daily, (~90 to 100 cherries) for just seven days prior to and on the day of the race. The attenuated pain in the cherry juice group suggests that even short term (~1 week) supplementation with tart cherry juice is effective at reducing the acute pain caused by repeated bouts of distance running. Our results are similar to those reported by Howatson et al. [27], in which runners who consumed tart cherry juice for 5 days prior to and 48 hours after a marathon showed faster recovery of muscle strength as well as reduced inflammation.

Due to methodological limitations, our results should be interpreted with caution. One limitation to the study was the subjective of assessment of pain by participants. However, the VAS is commonly used to determine acute levels of pain and has consistent and well-defined clinically meaningful thresholds [21, 28]. A second limitation is the possibility of cross contamination of the intervention and placebo drinks, as participants may have potentially switched drinks to compare flavor and effects. This limitation was addressed by assigning participants on the same relay team to the same beverage condition.

Conclusions

In conclusion, tart cherries have high levels of antioxidant and anti-inflammatory compounds, and are promoted in lay publications as beneficial for those with arthritis, muscle pain, and fibromyalgia. The nutraceutical industry is experiencing exponential growth and defining for whom these products might be beneficial is an important task. The present study suggests that the administration of tart cherry juice for eight days reduced symptoms of exercise-induced muscle pain among runners participating in a vigorous endurance event. Further research is needed to examine serum biomarkers and the potential explanation for the reduction in pain and inflammation associated with tart cherry consumption.

Notes

Declarations

Acknowledgements

No external funding was provided for this study. Cherrish Corporation (Seattle, WA) provided the cherry juice used in this study.

Authors’ Affiliations

(1)
Department of Medicine, Oregon Health & Science University
(2)
Department of Orthopedics, Oregon Health & Science University

References

  1. Papassotiriou I, Alexiou VG, Tsironi M, Skenderi K, Spanos A, Falagas ME: Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur J Clin Invest. 2008, 38: 276-279. 10.1111/j.1365-2362.2008.01935.x.View ArticlePubMedGoogle Scholar
  2. Millet GY, Lepers R: Alterations of neuromuscular function after prolonged running, cycling and skiing exercises. Sports Med. 2004, 34: 105-116. 10.2165/00007256-200434020-00004.View ArticlePubMedGoogle Scholar
  3. Kobayashi Y, Takeuchi T, Hosoi T, Yoshizaki H, Loeppky JA: Effect of a marathon run on serum lipoproteins, creatine kinase, and lactate dehydrogenase in recreational runners. Res Q Exerc Sport. 2005, 76: 450-455.View ArticlePubMedGoogle Scholar
  4. Cleak MJ, Eston RG: Muscle soreness, swelling, stiffness and strength loss after intense eccentric exercise. Br J Sports Med. 1992, 26: 267-272. 10.1136/bjsm.26.4.267.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Newham DJ, Jones DA, Ghosh G, Aurora P: Muscle fatigue and pain after eccentric contractions at long and short length. Clin Sci (Lond). 1988, 74: 553-557.View ArticleGoogle Scholar
  6. Newham DJ, Mills KR, Quigley BM, Edwards RH: Pain and fatigue after concentric and eccentric muscle contractions. Clin Sci (Lond). 1983, 64: 55-62.View ArticleGoogle Scholar
  7. Clarkson PM, Byrnes WC, Gillisson E, Harper E: Adaptation to exercise-induced muscle damage. Clin Sci (Lond). 1987, 73: 383-386.View ArticleGoogle Scholar
  8. McHugh MP, Pasiakos S: The role of exercising muscle length in the protective adaptation to a single bout of eccentric exercise. Eur J Appl Physiol. 2004, 93: 286-293. 10.1007/s00421-004-1196-0.View ArticlePubMedGoogle Scholar
  9. Tourville TW, Connolly DA, Reed BV: Effects of sensory-level high-volt pulsed electrical current ondelayed-onset muscle soreness. J Sports Sci. 2006, 24: 941-949. 10.1080/02640410500357226.View ArticlePubMedGoogle Scholar
  10. Pizza FX, McLoughlin TJ, McGregor SJ, Calomeni EP, Gunning WT: Neutrophils injure cultured skeletal myotubes. Am J Physiol Cell Physiol. 2001, 281: C335-41.PubMedGoogle Scholar
  11. Gorski T, Cadore EL, Pinto SS, da Silva EM, Correa CS, Beltrami FG, Kruel LF: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) in triathletes: Prevalence, level of awareness, and reasons for use. Br J Sports Med. 2009, doi:10.1136/bjsm.2009.062166.Google Scholar
  12. Howatson G, van Someren KA: The prevention and treatment of exercise-induced muscle damage. Sports Med. 2008, 38: 483-503. 10.2165/00007256-200838060-00004.View ArticlePubMedGoogle Scholar
  13. Seeram NP, Bourquin LD, Nair MG: Degradation products of cyanidin glycosides from tart cherries and their bioactivities. J Agric Food Chem. 2001, 49: 4924-4929. 10.1021/jf0107508.View ArticlePubMedGoogle Scholar
  14. Wang H, Nair MG, Strasburg GM, Chang YC, Booren AM, Gray JI, DeWitt DL: Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries. J Nat Prod. 1999, 62: 802-10.1021/np990184z.View ArticlePubMedGoogle Scholar
  15. Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP: Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage. Br J Sports Med. 2006, 40: 679-83. 10.1136/bjsm.2005.025429. discussion 683.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, Kader AA: Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003, 133: 1826-1829.PubMedGoogle Scholar
  17. Connolly DA, Sayers SP, McHugh MP: Treatment and prevention of delayed onset muscle soreness. J Strength Cond Res. 2003, 17: 197-208. 10.1519/1533-4287(2003)017<0197:TAPODO>2.0.CO;2.PubMedGoogle Scholar
  18. Singleton VJ, Rossi JA: Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am J Enol Vitic. 1965, 16: 144-158.Google Scholar
  19. Giusti MM, Wrolstad RE: Characterization and measurement with UV-visible spectroscopy. Current Protocols in Food Analytical Chemistry. Edited by: Wrolstad RE. 2001, New York, John Wiley & Sons, Inc, F1.2.1-13.Google Scholar
  20. Bijur PE, Silver W, Gallagher EJ: Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 2001, 8: 1153-1157. 10.1111/j.1553-2712.2001.tb01132.x.View ArticlePubMedGoogle Scholar
  21. Todd KH, Funk KG, Funk JP, Bonacci R: Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996, 27: 485-489. 10.1016/S0196-0644(96)70238-X.View ArticlePubMedGoogle Scholar
  22. Clarkson PM, Hubal MJ: Exercise-induced muscle damage in humans. Am J Phys Med Rehabil. 2002, 81: S52-69. 10.1097/00002060-200211001-00007.View ArticlePubMedGoogle Scholar
  23. Aoi W, Naito Y, Takanami Y, Kawai Y, Sakuma K, Ichikawa H, Yoshida N, Yoshikawa T: Oxidative stress and delayed-onset muscle damage after exercise. Free Radic Biol Med. 2004, 37: 480-487. 10.1016/j.freeradbiomed.2004.05.008.View ArticlePubMedGoogle Scholar
  24. Miles MP, Andring JM, Pearson SD, Gordon LK, Kasper C, Depner CM, Kidd JR: Diurnal variation, response to eccentric exercise, and association of inflammatory mediators with muscle damage variables. J Appl Physiol. 2008, 104: 451-458. 10.1152/japplphysiol.00572.2007.View ArticlePubMedGoogle Scholar
  25. Hirose L, Nosaka K, Newton M, Laveder A, Kano M, Peake J, Suzuki K: Changes in inflammatory mediators following eccentric exercise of the elbow flexors. Exerc Immunol Rev. 2004, 10: 75-90.PubMedGoogle Scholar
  26. Kelley DS, Rasooly R, Jacob RA, Kader AA, Mackey BE: Consumption of bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women. J Nutr. 2006, 136: 981-986.PubMedGoogle Scholar
  27. Howatson G, McHugh MP, Hill JA, Brouner J, Jewell AP, van Someren KA, Shave RE, Howatson SA: Influence of tart cherry juice on indices of recovery following marathon running. Scand J Med Sci Sports. 2009, doi: 10.1111/j.1600-0838.2009.01005.x.Google Scholar
  28. Gallagher EJ, Liebman M, Bijur PE: Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001, 38: 633-638. 10.1067/mem.2001.118863.View ArticlePubMedGoogle Scholar

Copyright

© Kuehl et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.